Amgen Stock Hits 52-Week High on Strong Earnings and Repatha Data

Amgen stock has been trading near its 52-week high after the biotech company reported strong Q2 2026 earnings and released new clinical data for its cholesterol drug Repatha.

The data, presented at the European Society of Cardiology Congress 2026, showed that Repatha reduced the risk of death for high-risk adults without prior heart attack or stroke, giving investors a new survival-data angle on a product already well established in the market.

Amgen's Q2 2026 earnings beat and raised parts of its guidance have underpinned the share price strength in recent weeks. The company reached a new 52-week high of $447.03 in late August 2026, with its market capitalization around $233 billion.

Repatha has long been part of Amgen's portfolio, but this new clinical update suggests that Repatha may have a stronger role in primary prevention for high-risk adults without a prior heart attack or stroke.